Skip to main content

Table 4 Summary of overall best response—efficacy population (N = 21)

From: Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma

 

Cohort 3

(Bel D1-3)

n = 7

Cohort 5 + Expansion

(Bel D1-5)

n = 14

Overall best response, n (%)

 CR

4 (57)

10 (71)

 PR

2 (29)

2 (14)

 SD

0

1 (7)

 PD

1 (14)

1 (7)

 Missing

0

0

Objective response rate

 CR, n (%)

4 (57)

10 (71)

  95% CI

18.41–90.10

41.90–91.61

 Objective response (CR + PR), n (%)

6 (86)

12 (86)

  95% CI

42.13–99.64

57.19–98.22